Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

SRL-172 associated with significantly improved survival in SCLC patients

March 28, 2000

Phase I clinical study to begin with Reolysin as cancer treatment

March 27, 2000

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

March 24, 2000

Phase I study of AltaRex's BrevaRex MAb completed

March 22, 2000

StressGen initiates phase II study with HspE7 in high-grade cervical dysplasia

March 22, 2000

FDA's ODAC recommends approval of Mylotarg for relapsed AML

March 21, 2000

Picower Institute presents new immunotherapeutic anticancer agents

March 17, 2000

Antisoma takes up another product from ICRF for clinical development

March 17, 2000

Low-dose M-Vax shows promise in stage III metastatic melanoma

March 17, 2000

Seattle Genetics updates MAb program

March 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...